3 Questions: AIDS researchers on new vaccine results

Sep 29, 2009
3 Questions: AIDS researchers on new vaccine results
Arup Chakraborty, MIT professor of chemical engineering, chemistry and biological engineering. Photo: Donna Coveney

(PhysOrg.com) -- On Thursday, an international research team reported that a new AIDS vaccine tested in more than 16,000 volunteers in Thailand protected a small but significant minority against infection. The new results mark the first time any vaccine has shown even partial success in clinical trials.

In this interview, Arup Chakraborty, MIT professor of chemical engineering, chemistry and biological engineering, and Bruce Walker, physician and investigator at Massachusetts General Hospital, share their thoughts on the new study.

Walker directs the Phillip T. and Susan M. Ragon Institute, a collaboration between MIT, Harvard and Massachusetts General Hospital launched earlier this year with a $100 million gift and the mission to develop an AIDS . Chakraborty is a team leader at the Institute.

Q: What is your reaction to the new study? How big a step forward is this in the search for an AIDS vaccine?

A: The data are clearly exciting because they are the first suggestion in humans that one might be able vaccinate people to lower the chance of getting infected with . The effect was very modest, so it is clear that this vaccine is not the answer, but it gives us important clues to follow to get to a vaccine with a stronger effect. These results also could end up not being significant - we don't yet know if the groups were matched for other possible confounding variables that affect transmission like HSV-2 infection and , which could influence the results.

Q: What challenges remain in the effort to develop an AIDS vaccine?

A: At the current time it is unclear what this vaccine did to provide weak protection, so it is unclear what needs to be boosted to make it better. Of 16,000 people in the trial, there were 70 infections in those that got a , and 51 in those that got a vaccine - not a huge benefit, but a signal nevertheless that the vaccine had some effect. The Ragon funding will allow us to move forward as quickly as possible to follow up on the clues from this trial.

Q: How does this advance affect the mission of the Ragon Institute, which was founded with the goal of developing an vaccine?

A: The data to us provide further support that an effective vaccine is possible. We have a long ways to go, but this is potentially a very important new clue to guide us.

Provided by Massachusetts Institute of Technology (news : web)

Explore further: Point-of-care CD4 testing is economically feasible for HIV care in resource-limited areas

add to favorites email to friend print save as pdf

Related Stories

AIDS vaccine trial exceeds expectations

Sep 23, 2005

An experimental AIDS vaccine of Merck & Co. has exceeded expectations and led to a double enrollment in the trial to 3,000, researchers said.

AIDS vaccine nears human testing

Aug 31, 2006

A University of Kansas Medical Center researcher hopes to get the funds needed for the next step in developing his AIDS vaccine -- testing on humans.

AIDS: No vaccine after 25 years

Jul 17, 2006

After 25 years and billions of research dollars the world's scientists have been unable to develop a vaccine that provides immunity against AIDS.

Experimental aids vaccine now in production

Nov 12, 2008

(PhysOrg.com) -- The advance towards a vaccine for HIV/AIDS has taken another step closer to realization. A vaccine, developed by Dr. Chil-Yong Kang and his team at the Schulich School of Medicine & Dentistry at The University ...

Puzzling results from HIV vaccine trial

Dec 03, 2007

A potential HIV vaccine that recently failed a clinical trial in the United States may increase some people's chance of catching the virus that causes AIDS.

Recommended for you

The genetics of coping with HIV

14 hours ago

We respond to infections in two fundamental ways. One, which has been the subject of intensive research over the years, is "resistance," where the body attacks the invading pathogen and reduces its numbers. Another, which ...

Long acting HIV drugs to be developed

Sep 11, 2014

HIV drugs which only need to be taken once a month are to be developed at the University of Liverpool in a bid to overcome the problem of 'pill fatigue'.

Puerto Rico partners on US HIV vaccine project

Sep 10, 2014

Puerto Rico's governor says the island's largest public university is partnering with federal agencies to oversee a U.S.-funded project aimed at trying to develop a prophylactic vaccine for the HIV virus that causes AIDS.

User comments : 0